Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced it is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neurodegenerative, renal, and cardiovascular diseases.

From Ubiquigent Limited 23 Jan 2023

BioEcho launches EchoLUTION™ Cell Culture RNA Kit for an efficient and simplified cell RNA extraction

BioEcho Life Sciences, the biotechnology company supplying fast and sustainable nucleic acid extraction technologies, announces the EchoLUTION Cell Culture RNA Kit launch, for an innovative total RNA extraction of any kind of cultured cells.

From BioEcho Life Sciences GmbH 23 Jan 2023

Experimental regenerative medicine shows potential to restore bone in an animal

Bone loss is a part of aging that compromises quality of life and movement in many older people, but regenerative treatments to improve their health and well-being have been limited.

19 Jan 2023

2023 EVIDENT Organoid Conference to share the latest organoid innovations

Building on the momentum from last year’s conference, the 2023 Evident Organoid Conference will highlight organoid innovations that are poised to accelerate progress in drug research and discovery.

From Evident Corporation - Life Sciences 18 Jan 2023

What does the future of clinical trials and evidence-based medicine look like?

In a recent perspective published in Nature Medicine, the researcher shared his vision and future perspectives for the domains of clinical research and evidence-based therapeutics.

18 Jan 2023

Novel peptide suppresses the damaging lung inflammation seen in ARDS

A novel peptide designed by University of California, Irvine researchers has been found to suppress the damaging lung inflammation seen in acute respiratory distress syndrome, or ARDS.

17 Jan 2023

Researchers identify inhibitors of the SARS-CoV-2 Nsp14 N7-methyltransferase

A recent study identified inhibitors for SARS-CoV-2 non-structural protein 14 (Nsp14).

17 Jan 2023

Optibrium appoints Steve Yemm as Chief Commercial Officer

New role will lead global commercial strategy and development as Optibrium continues to scale its drug discovery technologies and team.

From Optibrium Ltd. 17 Jan 2023

New cooling strategy could prevent the growth of glioblastoma

Cooling brain tumor cells to stop them from dividing without killing healthy cells extended the survival of glioblastoma (GBM) animal models dramatically in a study led by a UT Southwestern resident.

12 Jan 2023

Unique mass spectrometry-based approach to study specific changes in DNA after replication

A new method to study specific changes in DNA after replication has been published as a technical report in Nature Cell Biology.

12 Jan 2023

ADDF-Harrington partnership accelerates the translation of innovative Alzheimer's research into therapies

The Alzheimer's Drug Discovery Foundation and Harrington Discovery Institute at University Hospitals in Cleveland have granted an ADDF-Harrington Scholar Award to Christiane Wrann, PhD, DVM, Associate Professor in Medicine at the Cardiovascular Research Center and the McCance Center for Brain Health at Massachusetts General Hospital and the Harvard Medical School in Boston.

12 Jan 2023

Study may help explain how excess weight can contribute to diabetes

People who are overweight or obese have a significantly increased risk of developing diabetes, but exactly how that happens is not well understood.

11 Jan 2023

Developing new tools to accelerate spatial genomics and drug discovery

We speak to Dr. George Emanuel from Vizgen about their new MERSCOPE Platform and how it is accelerating the field of drug discovery by combining both single-cell and spatial genomics.

From Vizgen 10 Jan 2023

Using machine learning models to guide the design of long-acting injectable drug formulations

Scientists at the University of Toronto have successfully tested the use of machine learning models to guide the design of long-acting injectable drug formulations.

10 Jan 2023

Ubiquigent appoints Dr Xavier Jacq to Scientific Advisory Board

10 Jan 2023

New Bruker-Biognosys collaboration aims to deliver advanced proteomics CRO services

Bruker Corporation and Switzerland-based Biognosys AG today announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed. J.P.Morgan acted as exclusive financial advisor to Biognosys.

From Bruker BioSpin Group 10 Jan 2023

Clinically relevant biomarker strategies in drug development

In this interview, NewsMedical speaks with Dr. Justin Devine and Dr. Nicholas Woudberg about biomarkers, their importance for drug development as well as the potential they have when it comes to machine learning.

From Synexa Life Sciences 9 Jan 2023

High affinity antibodies isolated to safely target Claudin 6-positive tumors

Integral Molecular, the industry leader in antibody discovery for membrane proteins, has published the targeting mechanism enabling best-in-class specificity of its Claudin 6 (CLDN6) antibody CTIM-76 being developed for cancer therapy with Context Therapeutics.

6 Jan 2023

Researchers develop a new approach to better understand the biology of polycystic kidney disease

A research team supported by the National Institutes of Health has developed a new approach to better understand the biology of polycystic kidney disease (PKD), an often-life-threatening genetic disorder that affects millions worldwide.

5 Jan 2023

Insilico Medicine launches a 6th generation Intelligent Robotics Drug Discovery Laboratory

Insilico Medicine, a clinical stage, end-to-end artificial intelligence (AI)-driven drug discovery company, held the launch ceremony for Life Star – a 6th generation Intelligent Robotics Drug Discovery Laboratory – in Suzhou BioBAY Industrial Park on Dec. 29.

5 Jan 2023